1-5 of 5
Eric L. Sievers
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas, Mark D. Minden, Diego Villa, Mary-Elizabeth M. Percival, Anjali S. Advani, James M. Foran, Steven M. Horwitz, Matthew G. Mei, Jasmine Zain, Kerry J. Savage, Christiane Querfeld, Oleg E. Akilov, Lisa D.S. Johnson, Tina Catalano, Penka S. Petrova, Robert A. Uger, Eric L. Sievers, Anca Milea, Kathleen Roberge, Yaping Shou, Owen A. O'Connor
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (8): 2190–2199.
https://doi.org/10.1158/1078-0432.CCR-20-3706
Published: 15 April 2021
View article titled, Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

Penka S. Petrova, Natasja Nielsen Viller, Mark Wong, Xinli Pang, Gloria H.Y. Lin, Karen Dodge, Vien Chai, Hui Chen, Vivian Lee, Violetta House, Noel T. Vigo, Debbie Jin, Tapfuma Mutukura, Marilyse Charbonneau, Tran Truong, Stephane Viau, Lisa D. Johnson, Emma Linderoth, Eric L. Sievers, Saman Maleki Vareki, Rene Figueredo, Macarena Pampillo, James Koropatnick, Suzanne Trudel, Nathan Mbong, Liqing Jin, Jean C.Y. Wang, Robert A. Uger
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (4): 1068–1079.
https://doi.org/10.1158/1078-0432.CCR-16-1700
Published: 14 February 2017
View article titled, TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Open the PDF for TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding in another window
Includes: Supplementary data
Journal Articles

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Michelle A. Fanale, Andres Forero-Torres, Joseph D. Rosenblatt, Ranjana H. Advani, Anna R. Franklin, Dana A. Kennedy, Tae H. Han, Eric L. Sievers, Nancy L. Bartlett
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (1): 248–255.
https://doi.org/10.1158/1078-0432.CCR-11-1425
Published: 02 January 2012
View article titled, A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Open the PDF for A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

Nicole M. Okeley, Jamie B. Miyamoto, Xinqun Zhang, Russell J. Sanderson, Dennis R. Benjamin, Eric L. Sievers, Peter D. Senter, Stephen C. Alley
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (3): 888–897.
https://doi.org/10.1158/1078-0432.CCR-09-2069
Published: 01 February 2010
View article titled, Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Open the PDF for Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders

Madeleine Duvic, Sunil A. Reddy, Lauren Pinter-Brown, Neil J. Korman, John Zic, Dana A. Kennedy, Jennie Lorenz, Eric L. Sievers, Youn H. Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6217–6224.
https://doi.org/10.1158/1078-0432.CCR-09-0162
Published: 30 September 2009
View article titled, A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders
Open the PDF for A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders in another window